Clinical Report: Diffuse Subretinal Fibrosis and Uveitis Syndrome
Overview
This report documents a rare case of diffuse subretinal fibrosis and uveitis syndrome in a 67-year-old female, characterized by a significant gap in the onset of symptoms between the two eyes. The case highlights the complexities of managing associated vitreoretinal traction syndrome and retinal neovascularization.
Background
Diffuse subretinal fibrosis and uveitis (SFU) syndrome is a rare inflammatory condition that can lead to severe vision loss due to progressive subretinal fibrosis. Understanding its clinical presentation and management is crucial, as it often overlaps with other inflammatory chorioretinopathies, complicating diagnosis and treatment. The prognosis for SFU is generally poor, necessitating effective therapeutic strategies to manage inflammation and associated complications.
Data Highlights
No numerical data or trial data available in the article.
Key Findings
The patient experienced a 4-year gap between the onset of symptoms in each eye.
Best-corrected visual acuity was significantly low at 0.02 in the right eye and 0.05 in the left eye.
Fundus fluorescein angiography revealed secondary neovascular membranes in the left eye.
Post-surgery, the patient received glucocorticoids and immunosuppressive treatment, with partial response to anti-VEGF therapy for macular edema.
This case illustrates the complexities of SFU syndrome, particularly when complicated by vitreoretinal traction syndrome.
Clinical Implications
Clinicians should be aware of the potential for bilateral manifestations of SFU syndrome and the challenges in managing associated conditions such as vitreoretinal traction. Early intervention with glucocorticoids and immunosuppressive therapy may help manage inflammation, while anti-VEGF therapy can be considered for macular edema.
Conclusion
This case underscores the rarity and complexity of diffuse subretinal fibrosis and uveitis syndrome, particularly when accompanied by vitreoretinal traction. Ongoing research is needed to refine treatment strategies and improve patient outcomes.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
